Subcutaneously administered repronex® in oligoovulatory female patients undergoing ovulation induction is as effective and well tolerated as intramuscular human menopausal gonadotropin treatment

John E. Nichols, Eric Knochenhauer, Seymour Fein, Ronald V. Nardi, Dennis C. Marshall
In: Fertility and Sterility · 2001 · vol. 76(1) , pp. 58–66 · doi:10.1016/s0015-0282(01)01856-8 · PMID:11438320 · W1679507718
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Subcutaneous repronex® administration in oligoovulatory females undergoing ovulation induction demonstrated comparable efficacy and tolerability to intramuscular human menopausal gonadotropin treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo determine the efficacy and safety of Repronex SC as compared with Repronex IM and Pergonal IM in patients undergoing ovulation induction.DesignRandomized, open-label, multicenter, parallel group study.SettingTen academic and private fertility clinics with expertise in ovualtion induction.Patient(s)Premenopausal anovulatory and oligoovulatory females (n = 115) undergoing ovulation induction.Intervention(s)Down-regulation with leuprolide acetate followed by up to 12 days of treatment with gonadotropins and hCG administration and luteal phase progesterone support.Main outcome measure(s)Percentage of patients ovulating; percentage of cycles with follicular development meeting criteria for hCG administration; number of follicles recruited per cycle meeting hCG criteria; peak serum E(2) levels; rates of chemical, clinical and ongoing pregnancies; adverse events; injection-site pain scores.Result(s)There was no statistically significant difference in the percentage of women who ovulated among the treatment groups. However, Repronex SC was significantly more effective than Pergonal IM in producing follicular development in patients who met hCG criteria. There were no significant differences in clinical, ongoing, or continuing pregnancy rates or in multiple pregnancies among the treatment groups. No differences were found in the safety assessments, proportions or seriousness of adverse events or treatment discontinuations. Also, there were no differences between the three treatment groups in patient-recorded scores of injection-site pain or injection-site reactions.Conclusion(s)Repronex SC is as efficacious and well tolerated as Repronex IM or Pergonal IM in ovulation induction. Self-administration of Repronex SC provides a convenient treatment alternative to daily IM injections.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (1)

References (36)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-11T06:22:51.059792+00:00
License: CC0 · commercial use OK